BlogZone Get the app
Health

The billion-dollar problem keeping Ozempic, Wegovy, and Zepbound from patients

ScienceDaily Health 24 Jul 2026 1 views

Ozempic, Wegovy, and similar drugs may deliver excellent health value, but covering them for millions of eligible patients could overwhelm insurance budgets. Researchers say better long-term support is needed and warn that low-cost compounded versions may carry serious safety risks.

BlogZone shows headlines and summaries from public news feeds. The full story is published by ScienceDaily Health.

Read the full story at ScienceDaily Health →

Enjoyed this?

Get more stories like this — and write your own — in the BlogZone app.

Get the app

More in Health

Health

I'm burnt out and feel forgotten as a young carer

Min, 16, says people do not always understand her sacrifices and how valuable support is.

BBC Health · 2 hours ago
Health

Which antidepressants are the most effective?

Antidepressant escitalopram performed best at keeping depression symptoms away in a study involving nearly 10,000 people. But experts say the differences between medications were small.

BBC Health · 3 hours ago
Health

Common forever chemicals linked to nearly double the rate of aggressive breast cancer

An NIH study found that women with high levels of two common “forever chemicals” had up to 93% higher rates of an aggressive form of breast cancer. The discovery raises concerns about the potential he

ScienceDaily Health · 5 hours ago